Evidence map›Paper›PMID 36770718›Full record

ArticleMolecules (Basel, Switzerland)2023

Characterization of Galectin Fusion Proteins with Glycoprotein Affinity Columns and Binding Assays.

Carina Dey, Philip Palm, Lothar Elling

Abstract read
In one paragraph

Article in Molecules (Basel, Switzerland), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Carina DeyLaboratory for Biomaterials, Institute for Biotechnology and Helmholtz-Institute for Biomedical Engineering, RWTH Aachen University, Pauwelsstraße 20, 52074 Aachen, Germany.ORCID 0000-0002-9395-1344
Philip PalmLaboratory for Biomaterials, Institute for Biotechnology and Helmholtz-Institute for Biomedical Engineering, RWTH Aachen University, Pauwelsstraße 20, 52074 Aachen, Germany.ORCID 0000-0001-5945-3600
Lothar EllingLaboratory for Biomaterials, Institute for Biotechnology and Helmholtz-Institute for Biomedical Engineering, RWTH Aachen University, Pauwelsstraße 20, 52074 Aachen, Germany.ORCID 0000-0002-3654-0397

Funding

Deutsche Forschungsgemeinschaft Collaborative Research Center (CRC) grant SFB 985 project C3European Cooperation in Science and Technology EU COST action CA18132 GLYCONanoPROBES
6 · The paper itself

Abstract

Galectins are β-galactosyl-binding proteins that fulfill essential physiological functions. In the biotechnological field, galectins are versatile tools, such as in the development of biomaterial coatings or the early-stage diagnosis of cancer diseases. Recently, we introduced galectin-1 (Gal-1) and galectin-3 (Gal-3) as fusion proteins of a His

Indexed as

GalectinsGlycoproteinsBenzamidesCell MembraneGalectin 3Protein BindingTyrosine1-nitrohydroxyphenyl-N-benzoylalanineBenzamidesGalectin 3GalectinsGlycoproteinsTyrosineELISAextracellular matrix proteinGal-1Gal-3Gal-8CGal-8Ngalectin fusion proteingalectin purificationglycoproteinSNAP-tag

Identifiers

PMID36770718
PMCPMC9919667

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.